Earnings Call · Q2 FY2023·2023-08-06

Q2 23EPS +5.36%·Rev n/aQ1 23EPS +7.41%·Rev n/aQ4 22EPS +14.04%·Rev n/aQ3 22EPS +5.36%·Rev n/a⚠ consensus missing

Kura Oncology, Inc. KURA

Pete De Spain — Investor Relations or Communications

Troy Wilson — President and Chief Executive Officer

Tom Doyle — Senior Vice President of Finance and Accounting

+2.6%1d on move date+2.9% vs SPY3d+1.6%5d+4.8%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more KURA calls or request research access.

More KURA calls Browse calls Request research access